These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 18663285)
1. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Mori Y; Kosaki A; Kishimoto N; Kimura T; Iida K; Fukui M; Nakajima F; Nagahara M; Urakami M; Iwasaka T; Matsubara H Am J Nephrol; 2009; 29(1):18-24. PubMed ID: 18663285 [TBL] [Abstract][Full Text] [Related]
2. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Kim JK; Park S; Lee MJ; Song YR; Han SH; Kim SG; Kang SW; Choi KH; Kim HJ; Yoo TH Atherosclerosis; 2012 Jan; 220(1):208-14. PubMed ID: 21906738 [TBL] [Abstract][Full Text] [Related]
3. Do elevated plasma S100A12 levels predict atherosclerosis in peritoneal dialysis patients? Yayar O; Eser B; Buyukbakkal M; Erdogan B; Ercan Z; Merhametsiz O; Haspulat A; Kali A; Yildirim T; Canbakan B; Ayli MD Ren Fail; 2015 Jun; 37(5):845-50. PubMed ID: 26016405 [TBL] [Abstract][Full Text] [Related]
4. Circulating levels of soluble receptor for advanced glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent of S100A12 (EN-RAGE) levels. Kim HS; Chung W; Kim AJ; Ro H; Chang JH; Lee HH; Jung JY Nephrology (Carlton); 2013 Dec; 18(12):777-82. PubMed ID: 24124651 [TBL] [Abstract][Full Text] [Related]
5. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. Kosaki A; Hasegawa T; Kimura T; Iida K; Hitomi J; Matsubara H; Mori Y; Okigaki M; Toyoda N; Masaki H; Inoue-Shibata M; Nishikawa M; Iwasaka T J Clin Endocrinol Metab; 2004 Nov; 89(11):5423-8. PubMed ID: 15531492 [TBL] [Abstract][Full Text] [Related]
6. Associations between Soluble Receptor for Advanced Glycation End Products (sRAGE) and S100A12 (EN-RAGE) with Mortality in Long-term Hemodialysis Patients. Jung ES; Chung W; Kim AJ; Ro H; Chang JH; Lee HH; Jung JY J Korean Med Sci; 2017 Jan; 32(1):54-59. PubMed ID: 27914132 [TBL] [Abstract][Full Text] [Related]
7. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients. Isoyama N; Leurs P; Qureshi AR; Bruchfeld A; Anderstam B; Heimburger O; Bárány P; Stenvinkel P; Lindholm B Nephrol Dial Transplant; 2015 Jan; 30(1):84-91. PubMed ID: 25074436 [TBL] [Abstract][Full Text] [Related]
8. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Nakashima A; Carrero JJ; Qureshi AR; Miyamoto T; Anderstam B; Bárány P; Heimbürger O; Stenvinkel P; Lindholm B Clin J Am Soc Nephrol; 2010 Dec; 5(12):2213-9. PubMed ID: 20847094 [TBL] [Abstract][Full Text] [Related]
9. Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Mahajan N; Malik N; Bahl A; Dhawan V Atherosclerosis; 2009 Dec; 207(2):597-602. PubMed ID: 19576587 [TBL] [Abstract][Full Text] [Related]
10. Serum S100A12 (EN-RAGE) levels in patients with decreased renal function and subclinical chronic inflammatory disease. Zakiyanov O; Kalousová M; Kříha V; Zima T; Tesař V Kidney Blood Press Res; 2011; 34(6):457-64. PubMed ID: 21822023 [TBL] [Abstract][Full Text] [Related]
11. Plasma S100A12 concentrations in peritoneal dialysis patients and subclinical chronic inflammatory disease. Uchiyama-Tanaka Y; Mori Y; Kosaki A; Kimura T; Moriishi M; Kawanishi H; Matsubara H Ther Apher Dial; 2008 Feb; 12(1):28-32. PubMed ID: 18257809 [TBL] [Abstract][Full Text] [Related]
12. Plasma levels of the pro-inflammatory protein S100A12 (EN-RAGE) are associated with muscle and fat mass in hemodialysis patients: a cross-sectional study. Fukasawa H; Ishigaki S; Kinoshita-Katahashi N; Yasuda H; Kumagai H; Furuya R Nutr J; 2014 May; 13():48. PubMed ID: 24884769 [TBL] [Abstract][Full Text] [Related]
13. Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease. Ueno H; Koyama H; Fukumoto S; Tanaka S; Shoji T; Shoji T; Emoto M; Tahara H; Inaba M; Kakiya R; Tabata T; Miyata T; Nishizawa Y Metabolism; 2011 Apr; 60(4):453-9. PubMed ID: 20494372 [TBL] [Abstract][Full Text] [Related]
14. Atherosclerosis is associated with plasminogen activator inhibitor type-1 in chronic haemodialysis patients. Peng Y; Liu H; Liu F; Ouyang L; Cheng M; Gao L; Pan F; Liu Y; Chen X; Li J Nephrology (Carlton); 2008 Oct; 13(7):579-86. PubMed ID: 19161364 [TBL] [Abstract][Full Text] [Related]
16. High levels of S100A12 are associated with recent plaque symptomatology in patients with carotid atherosclerosis. Abbas A; Aukrust P; Dahl TB; Bjerkeli V; Sagen EB; Michelsen A; Russell D; Krohg-Sørensen K; Holm S; Skjelland M; Halvorsen B Stroke; 2012 May; 43(5):1347-53. PubMed ID: 22382154 [TBL] [Abstract][Full Text] [Related]
17. Inflammation as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis in haemodialysis patients: the role of chlamydia and cytomegalovirus infection. Buyukhatipoglu H; Tiryaki O; Tahta K; Usalan C Nephrology (Carlton); 2007 Feb; 12(1):25-32. PubMed ID: 17295657 [TBL] [Abstract][Full Text] [Related]
18. S100A12 gene expression is increased in peripheral leukocytes in chronic kidney disease stage 4-5 patients with cardiovascular disease. Hara M; Ando M; Morito T; Nokiba H; Iwasa Y; Tsuchiya K; Nitta K Nephron Clin Pract; 2013; 123(3-4):202-8. PubMed ID: 23921255 [TBL] [Abstract][Full Text] [Related]
19. Soluble RAGE and the RAGE ligands HMGB1 and S100A12 in critical illness: impact of glycemic control with insulin and relation with clinical outcome. Ingels C; Derese I; Wouters PJ; Van den Berghe G; Vanhorebeek I Shock; 2015 Feb; 43(2):109-16. PubMed ID: 25394242 [TBL] [Abstract][Full Text] [Related]
20. S100A12 and soluble receptor for advanced glycation end products levels during human severe sepsis. Achouiti A; Föll D; Vogl T; van Till JW; Laterre PF; Dugernier T; Wittebole X; Boermeester MA; Roth J; van der Poll T; van Zoelen MA Shock; 2013 Sep; 40(3):188-94. PubMed ID: 23846410 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]